Clinical Trial Update: A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for navicixizumab in platinum-resistant ovarian cancer is underway, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Navicixizumab (navicixizumab)

Snippet

Sponsor: OncXerna Theraputics, Inc. | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Status: UNKNOWN